Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,013.20 +913.34 (+1.36%) CMC Crypto 200
1,374.23 +43.62 (+3.28%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
After hours:
| Previous close | 1.6800 |
| Open | 1.6800 |
| Bid | 1.6200 x 100 |
| Ask | 1.7700 x 100 |
| Day's range | 1.6100 - 1.7400 |
| 52-week range | 1.3000 - 11.4000 |
| Volume | |
| Avg. volume | 834,896 |
| Market cap | 2.488M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -22.0200 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.00 |
ZacksCyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GlobeNewswireCyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Lengthens Patent Exclusivity of Plogosertib until August 2040BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor.
ZacksAll You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
